Phase 3
N=424
A Severity-Adapted Clinical Trial of Diminished Bone Mineral Density in Acute Lymphoblastic Leukemia Survivors
Leukemia, Lymphoblastic, Acute · Osteoporosis
Bottom Line
View on ClinicalTrials.gov: NCT00186901 ↗Enrolled (actual)
424
Serious AEs
0.0%
Results posted
Mar 2012
Primary outcome: Primary: Effect of Taking Calcium and Vitamin D Supplements on Bone Mineral Density (BMD) — -0.95; -0.97; -0.87; -1.04 Z-Score — p=0.86
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 3
- Interventions
- Calcium carbonate (Tums), vitamin D (Drug); Placebo (Other)
- Age
- Pediatric, Adult, Older Adult
- Sex
- All
- Sponsor
- St. Jude Children's Research Hospital
- Primary completion
- Jun 2009
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Effect of Taking Calcium and Vitamin D Supplements on Bone Mineral Density (BMD) |
-0.95; -0.97; -0.87; -1.04; -0.72; -0.76 | 0.86 |
| PRIMARY Bone Mineral Density in Male and Female ALL Survivors |
-0.62; -0.3 | 0.0004 sig |
| PRIMARY Bone Mineral Density by Race of ALL Survivors |
-0.54; 0.15 | 0.0023 sig |
| PRIMARY Bone Mineral Density by Age Group of ALL Survivors |
-0.6; -0.54; -0.59; -0.25 | 0.0092 sig |
| SECONDARY Quantitative Computed Tomography (QCT) and Dual Energy X-ray Absorptiometry (DXA) Scan Scores for Bone Mineral Density. |
-0.54; -0.63; -0.71; -0.63 | <0.0001 sig |
| SECONDARY Quantitative Computed Tomography (QCT) and Dual Energy X-ray Absorptiometry (DXA) Scan Scores for Bone Mineral Density. |
-0.54; -0.63; -0.71; -0.63 | <0.0001 sig |
| SECONDARY Quantitative Computed Tomography (QCT) and Dual Energy X-ray Absorptiometry (DXA) Scan Scores for Bone Mineral Density. |
-0.54; -0.63; -0.71; -0.63 | <0.0001 sig |
| SECONDARY Quantitative Computed Tomography (QCT) and Dual Energy X-ray Absorptiometry (DXA) Scan Scores for Bone Mineral Density. |
-0.54; -0.63; -0.71; -0.63 | <0.0001 sig |
| SECONDARY Mean QCT Z-Score by Apa1 Vitamin D Receptor Genotype |
-0.56; -0.44; -0.57 | 0.40 |
| SECONDARY Mean QCT Z-Score by Bsm 1 Vitamin D Receptor Genotype |
-0.5; -0.17; -0.17 | 0.21 |
Summary
Research studies have shown that children who are long-term survivors of childhood leukemia may be at greater risk for early bone loss called osteoporosis. This bone loss may lead to a greater risk of broken bones and other spine and bone problems. However, researchers still do not know much about how frequently this long-term side effect may occur and how severe the problem is.
St. Jude Children's Research Hospital researchers want to determine the frequency and severity of this side effect. They are also studying whether taking calcium and Vitamin D supplements can help children at risk for osteoporosis and if certain factors can be identified -- such as age at diagnosis, cancer treatments, or family history -- that may increase the chances of having osteoporosis. Researchers will take an x-ray study called quantitative computed tomography (QCT) to measure bone mineral density (BMD). The BMD is a measure of bone strength. If a subject's BMD falls below the average, he/she will be assigned to one of two groups. Subjects will be randomly assigned (like tossing a coin) to receive calcium and vitamin D pills. The other half will receive placebo pills that look like the calcium and vitamin D pills.
Eligibility Criteria
Inclusion Criteria
- Patient is a survivor of acute lymphoblastic leukemia.
- Patient was treated on St. Jude Children's Research Hospital's Total XI, XII, or XIII treatment protocol.
- Patient is at least five years out from completion of therapy and is in first remission
Exclusion Criteria
- Active disease
- Pregnant or lactating females
- Inability to chew and swallow pills
- Currently taking more than 800 mg supplemental calcium or 800 IU vitamin D
- Anemia
Data sourced from ClinicalTrials.gov (NCT00186901). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.